Press releases
- 4basebio Plc - 4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program
- 4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
- 4basebio Plc - 4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
Key statistics
As of last trade 4Basebio PLC (88Q:FRA) traded at 16.20, -5.81% below its 52-week high of 17.20, set on May 15, 2024.
52-week range
Open | 16.20 |
---|---|
High | 16.20 |
Low | 16.20 |
Bid | 16.00 |
Offer | 18.70 |
Previous close | 16.20 |
Average volume | 373.78 |
---|---|
Shares outstanding | 12.81m |
Free float | 3.89m |
P/E (TTM) | -- |
Market cap | 179.91m GBP |
EPS (TTM) | -0.5094 GBP |
Data delayed at least 15 minutes, as of May 24 2024 14:29 BST.
More ▼